Director, Gynecologic Oncology and CoChair, Cancer Research Committee, Mount Sinai Medical Center, Board of Directors and Uterine Cancer Lead, GOG Foundation
Miami Beach, FL
Joined April 2009
- Tweets863
- Following1.7K
- Followers3K
- Likes854
Brian Slomovitz, MD, MS, FACOG retweeted
Can dMMR Endometrial Cancer Go Chemo-Free in the First Line?
Can dMMR endometrial cancer go chemo-free in 1L?
KEYNOTE-C93: pembrolizumab monotherapy improved PFS vs carboplatin–paclitaxel; OS is still immature.
Magnitude of benefit & toxicity await LBA12.
@GynCancerMD @myESMO @GOG
#ESMO26 #GynOnc
Brian Slomovitz, MD, MS, FACOG retweeted
Rare Ovarian Cancers: Progress, Advances & Hope Ahead by Dr. @GynCancerMD at our recently hosted annual conference, Ovarcoming Cancer, 2026.
WATCH full video here: youtu.be/6-cyCte5zhk?si=T5x7…
Looking forward to speaking with @ovarcome Annual Global Conference during Ovarian Cancer Awareness Month. @TurnTownsTeal @MountSinaiMiami @GOG @IJGConline
Register via this link ⬇️ : ovarcome.org/ovarcoming-canc…
Our 14th Annual Global Conference is on September 17-18.
We are honored to announce our third Speaker, Dr. @GynCancerMD! One of the leading global experts in Low Grade Serous Ovarian Cancer, Dr. Slomovitz has been at the forefront of practice changing pivotal trials to improve outcomes for the LGSOC community. 🙏🏼
Dr. Slomovitz will be joining us to Talk About Rare Ovarian Cancers: Progress, Advances & Hope Ahead.
Join us for our 2 day Annual Conference and please share with anyone who may benefit - it is FREE, as knowledge should be!
Dr. Slomovitz invites you! 🩵
Ask. Learn. Share. Be EMPOWERED!
#OvarCon2026
Brian Slomovitz, MD, MS, FACOG retweeted
NEWS FROM INDUSTRY: KEYNOTE-C93 Update in #EndometrialCancer
Source: Merck press release
The Phase 3 KEYNOTE-C93 trial showed pembrolizumab monotherapy significantly improved progression-free survival compared with platinum-based chemotherapy in patients with previously untreated advanced or recurrent endometrial cancer with mismatch repair deficient (dMMR) tumors. The study demonstrated meaningful response rates, complete responses, and durable responses, with a safety profile consistent with prior pembrolizumab studies. Results suggest a potential chemotherapy-free frontline treatment option for this patient population.
buff.ly/KUyVpCI
@agz_eriksson
@ESGO_society
@IJGConline
@NicoloBizzarri
@nataliagandur
@realbowtiedoc
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@amandaNizamMD
@DrVilmaPBarcia
Brian Slomovitz, MD, MS, FACOG retweeted
#ESMOGynae26: Data from two #ClinicalTrials provide long-term #EfficacyAndSafety evidence for the #CheckpointInhibitor dostarlimab, suggesting that immunotherapy may be used w/ curative intent in #EndometrialCancer. #ESMODailyReporter➡️ow.ly/QXHh50ZefTX
@GynCancerMD
Going to be a great sgo. Congrats @PamSolimanMD program director (my co-fellow) and @karenluMD, SGO President (one of my mentors and my fellowship research boss) for organizing a great meeting. It’s going to be fun and educational!!
🔬 Ahead of #SGO2026 , experts highlight the presentations they’re most excited about:
@DrMaurieMarkman: FDA therapy & early-phase trial updates
@GynCancerMD: Ongoing ovarian, uterine & cervical cancer studies
📈 Get the full preview:
hubs.li/Q04b4Gj-0
Brian Slomovitz, MD, MS, FACOG retweeted
Florida is showing up in a big way for #OLNGreatDebates this March in Miami!
We’re proud to welcome an exceptional group of faculty from across the state, representing @MoffittNews, @SylvesterCancer, @MayoClinic, Memorial Cancer Institute, @AdventHealth, @MountSinaiMiami, @OncologyInst, and @MiamiCancerInst.
Take a look at their debates: hmpglobalevents.com/olngreat…
#Oncology #MedicalOncology #GICancer #LungCancer #BreastCancer #GUCancer #GynecologicOncology
Brian Slomovitz, MD, MS, FACOG retweeted
Is immunotherapy the right frontline strategy for all patients with metastatic endometrial cancer? Or should treatment be guided by molecular profiling?
Join @johndiazmd, Miami Cancer Institute, and @GynCancerMD, MD, Florida International University, for a compelling debate:
Front-Line Metastatic Endometrial Cancer: Immunotherapy for All vs Molecular Profiling to Individualize Therapy
This session will:
▪️ Examine clinical trial data supporting broad immunotherapy use
▪️ Evaluate evidence for molecular subtype-guided treatment selection
▪️ Discuss real-world application and practical decision-making
▪️ Explore how evolving data are reshaping personalized care
Don’t miss this expert discussion on where the evidence stands and where frontline care is headed.
Brian Slomovitz, MD, MS, FACOG retweeted
Standard post-operative platinum chemotherapy for LGSOC is a biological fossil, a high-grade protocol forced onto an endocrine-driven disease where response rates struggle to break 13%. We must stop defaulting to this “platinum sprint” and shape the field around the #GOG3026 results (ribociclib + letrozole), showing a 30.6% ORR and a 21.2-month DOR in first-line recurrence, prioritizing durability and quality of life upfront while reserving the high-pressure strike of MEK/FAK inhibition for second-line progression, where avutometinib + defactinib achieves a 44% ORR in KRAS-mutated cohorts. To truly move the needle, we must challenge the necessity of adjuvant platinum altogether, moving endocrine-targeted strategies into frontline maintenance or as a complete replacement for cytotoxic therapy post-surgery. If the biology is distinct, the standard of care must be too: logic over tradition.
#LGSOC #GynOnc #OncTwitter #PrecisionMedicine #TargetedTherapy @GynCancerMD @ocrahope @OncoAlert
ascopubs.org/doi/10.1200/JCO…
targetedonc.com/view/beyond-…
We have a new treatment options for patients with low grade serous ovarian cancer (LGSOC). Great news for our patients!
@GOG @NotTheseOvaries @TargetedOnc @MSMCObGyn
Brian Slomovitz, MD, MS, FACOG retweeted
I Treat Cervical Cancer in 2026 – OncoDaily Summit
During the Summit, leading experts Mansoor Raza Mirza (@MirzaCPH), Brian Slomovitz (@GynCancerMD) and Giuseppe Caruso, (@gcarusomd) came together for an in-depth discussion on the evolving landscape of cervical cancer care.
🔬 Key topics explored:
• Role of Systemic Therapy in Early-Stage Cervical Cancer: What and When?
• Immunotherapy in Localized Cervical Cancer: Current strategies and emerging approaches
• Novel Weapons in Treating Cervical Cancer: Cutting-edge treatments and future directions
This session emphasized the importance of innovation, multidisciplinary collaboration, and personalized therapy in improving outcomes for patients with cervical cancer worldwide.
Watch live on YouTube :
lnkd.in/df8dTZrw
Also streaming on X (Twitter) Live:
lnkd.in/d3K63aRs
#CervicalCancer #Radiotherapy #OncologicSurgery #ImagingInOncology #HPVPrevention #WomensHealth #CancerCare2026
aacrjournals.org/clincancerr…
GLP-1 Receptor Agonists (Ozempic, Mounjaro, Zepbound) are changing the world. I’m convinced it will help prevent and treat endometrial cancer. This review discusses this gamechanger. @MountSinaiMiami @GOG
reachmd.com/programs/cme/opt…
If interested, here is a grand rounds on cervical and endometrial cancer and latest landscape.
Brian Slomovitz, MD, MS, FACOG retweeted
#IGCS2025 Congratulations Dr. Ledermann!! Are we back to weekly dd paclitaxel?? Looking forward to translational studies ❤️🥰❤️
Brian Slomovitz, MD, MS, FACOG retweeted
#LeadArticle Checkpoint inhibitor rechallenge in advanced #endometrialcancer: revisiting the immune landscape beyond first-line therapy
✅ bit.ly/48W0QIh
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul @GynCancerMD @VPodder
Brian Slomovitz, MD, MS, FACOG retweeted
Join us tomorrow, October 14 at 12:30 PM CST, as we Connect Ovar Coffee ☕️ with Dr. @GynCancerMD exclusively on our YouTube, to Talk About the Latest Advances in Ovarian & Gynecologic Cancers.
Be there. Be informed. Be empowered. 💪
Let’s #ConnectOvarCoffee! ☕️
foxnews.com/health/weight-lo…
GLP-1 use decreases the risk of most cancers, including endometrial and ovarian cancers. Honored to discuss this potential “gamechanger” with @FoxNews
@GOG @MountSinaiMiami
Onclive State of the Science Coming to Miami 10/30
Hosted by @OncLive @MountSinaiMiami
Join us for a great way to learn and to network with friends and colleagues. So honored have this distinguished group of Key Opinion Leaders as speakers @DrKatyMoore @IJGConline @GOG
thepatientstory.com/patient-…
Join us for an update on endometrial cancer.
@thepatientstory @MountSinaiMiami
